Skip to main content
Novonesis AS logo

Novonesis AS — Investor Relations & Filings

Ticker · NSIS ISIN · DK0060336014 LEI · 529900T6WNZXD2R3JW38 CO Manufacturing
Open in API
Filings indexed 2,308 across all filing types
Latest filing 2007-11-01 Director's Dealing
Country DK Denmark
Listing CO NSIS

About Novonesis AS

https://www.novozymes.com/en

Novonesis is a global biosolutions company formed through the combination of Novozymes and Chr. Hansen. The company develops and produces a broad portfolio of biological solutions, including industrial enzymes, functional proteins, and microorganisms such as cultures, probiotics, and yeast. Its products are utilized in over 30 industries to improve efficiency, sustainability, and product quality. Key markets include food and beverage, where solutions enhance nutrition and reduce waste; human and animal health; agriculture, promoting higher crop yields and animal welfare; and household care, for more effective cleaning. Novonesis applies biotechnological principles to address global challenges in production and consumption, aiming to create more sustainable systems and products.

Recent filings

Filing Released Lang Actions
Director's Dealing 2007
Director's Dealing Classification · 99% confidence The document explicitly states 'TRADING BY INSIDERS IN NOVOZYMES A/S B SHARES' and details a transaction made by a 'Vice chairman of the board' on a specific date, including the number of shares traded and market value. This directly corresponds to the definition of Director's Dealing (insider trades). Reviewing the definitions: - 10-K/IR/ER/MRQ/MDA: Not a comprehensive financial report or earnings release. - DIV/CAP/SHA/POS: Not primarily about dividends, financing, or share issuance/repurchase, but about insider trading. - The content perfectly matches the description for Director's Dealing (Code: DIRS): 'Report of personal share transactions by company directors and executives (insider trades)'. - The document length is short (1895 chars), but it is the full report of the transaction, not an announcement of a separate, larger report, so RPA/RNS is not the primary classification.
2007-11-01 English
M&A Activity 2007
M&A Activity Classification · 99% confidence The document is a formal announcement dated October 31, 2007, detailing Novozymes' intention to make a cash tender offer (købstilbud) to acquire all shares of Philom Bios Inc. for CAD 6.50 per share. This describes a specific corporate action involving a takeover bid or merger proposal. Based on the definitions, this clearly falls under 'M&A Activity' (Code: TAR), which covers merger proposals or takeover bids. The document is a direct announcement of the offer, not a general regulatory filing (RNS) or a report itself.
2007-10-31 Danish
M&A Activity 2007
M&A Activity Classification · 99% confidence The document explicitly announces a 'take-over bid' by Novozymes for all shares in Philom Bios Inc., detailing the offer price (CAD 6.50 per share), the total equity value (CAD 25.6 million), and the strategic rationale. This content directly relates to a merger or acquisition proposal. Based on the definitions, the code 'TAR' (M&A Activity) is the most appropriate classification for announcements related to merger proposals or takeover bids.
2007-10-31 English
M&A Activity 2007
M&A Activity Classification · 99% confidence The document is a formal announcement dated October 31, 2007, detailing Novozymes' intention to make a cash tender offer (købstilbud) to acquire all shares of Philom Bios Inc. for CAD 6.50 per share. This describes a specific corporate action involving a takeover bid or merger proposal. Based on the definitions, this clearly falls under 'M&A Activity' (Code: TAR), which covers merger proposals or takeover bids. The document is a direct announcement of the offer, not a general regulatory filing (RNS) or a report itself.
2007-10-31 Danish
Legal Proceedings Report 2007
Legal Proceedings Report Classification · 99% confidence The document is titled "COMPANY ANNOUNCEMENT 17/2007" and discusses an ongoing situation involving Carlsberg A/S, Heineken N.V., and Scottish & Newcastle plc (S&N). The content focuses on a consortium urging S&N to engage regarding a takeover proposal (mentioning a price of 720p per share) and notes S&N's initiation of arbitration proceedings. Crucially, the document includes detailed sections on "Dealing Disclosure Requirements" referencing Rule 8.3 and Rule 8.1 of the "Takeover Code" and the "Takeover Panel." This specific regulatory language strongly indicates activity related to a takeover bid or merger proposal. Therefore, the most appropriate classification is M&A Activity (TAR). The document is an announcement related to a takeover situation, not a general regulatory filing (RNS) or a formal report.
2007-10-31 English
Regulatory Filings 2007
Regulatory Filings
2007-10-01 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.